Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days.

Trial Profile

Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2011

At a glance

  • Drugs Mesothelin SS dsFv PE38 (Primary)
  • Indications Cervical cancer; Head and neck cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2008 'National Cancer Institute - Center for Cancer Research-Medical Oncology' added as study sponsor as reported by ClinicalTrials.gov.
    • 15 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top